RxDoctor Payments DataLook up a doctor →

Martin Gutierrez, MD

Medical Oncology · Hackensack, NJNPI 1558562793

Payments from drug & device makers

$41,832,211in general payments, 2019–2025

Across 5,040 payments — averaging $8300.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$12M
  • Merck$10.7M
  • Incyte Corporation$7.8M
  • Sanofi US Services Inc.$1.4M
  • Daiichi Sankyo Inc.$1.2M
  • Pfizer$1M
  • plus $7.7M from 49 others
$6,441in research payments, 2019–2025

Across 9 payments — averaging $715.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$4K
  • Boehringer Ingelheim$1K
  • Bristol Myers Squibb$1K
  • E.r. Squibb & Sons, L.L.C.$65

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.197$11,960,431
Merck713$10,666,683
Incyte Corporation2,572$7,807,049
Sanofi US Services Inc.110$1,404,815
Daiichi Sankyo Inc.323$1,244,514
Pfizer104$1,043,369
AstraZeneca15$976,128
Boehringer Ingelheim49$834,798
Janssen Research & Development, LLC108$640,129
Array Biopharma Inc81$592,087
Astrazeneca UK Limited7$581,635
Beigene, Ltd.54$579,562
Amgen9$485,251
Seagen Inc.71$414,204
F. Hoffmann-la Roche AG47$410,037
Modernatx, Inc.115$344,941
Novartis10$246,592
Regeneron27$244,137
Mirati Therapeutics, Inc.33$195,326
Boehringer Ingelheim International GmbH82$182,141
Beone Medicines USA, Inc.20$135,579
Tesaro, Inc.17$119,561
EMD Serono, Inc.20$101,141
Bristol Myers Squibb6$90,495
Beone Medicines Ltd.19$77,625
Nuvation Bio Inc.37$58,404
Beigene USA, Inc.24$58,081
GSK17$57,181
Biontech SE12$56,816
Genentech, Inc.9$44,511
Bayer11$44,464
Astellas Pharma Global Development6$42,620
Roche Products Limited35$34,238
AbbVie10$21,932
Hoffmann-la Roche Limited1$17,800
Boehringer Ingelheim Pharma GmbH & Co.kg26$6,263
Acerta Pharma LLC1$4,391
Organon1$2,500
Celularity Inc.4$2,098
Eisai Inc.5$2,070
Ipsen Biopharmaceuticals, Inc8$136
Gilead1$118
Johnson & Johnson5$85
Genentech USA, Inc.3$40
Takeda Pharmaceuticals U.S.A., Inc.3$40
Deciphera Pharmaceuticals Inc.2$33
Blueprint Medicines Corporation2$30
Taiho Oncology, Inc.1$23
Pharmacosmos Therapeutics Inc.1$17
Jazz Pharmaceuticals Inc.1$17
Tempus AI, Inc1$17
Helsinn Therapeutics (U.S.), Inc.1$15
Astellas Pharma US Inc1$14
Lilly USA, LLC1$14
Servier Pharmaceuticals LLC1$13

How this compares

$41,832,211 in reported general payments places this provider in the 95th percentile of 112 medical oncology providers in New Jersey.

See all medical oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024
$1,003,642
Medicare patients
661
Services billed
49,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Hackensack

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →